Hepatobiliary damage and changes in hepatic gene expression caused by the antitumor drug ecteinascidin-743 (ET-743) in the female rat

• Published in: Cancer research (Chicago, Ill.) Vol. 62; no. 15; pp. 4256 - 4262
• Main Authors: DONALD, Sarah, VERSCHOYLE, Richard D, GREAVES, Peter, GESCHER, Andreas J, EDWARDS, Richard, JUDAH, David J, DAVIES, Reginald, RILEY, Joan, DINSDALE, David, LOPEZ LAZARO, Luis, SMITH, Andrew G, GANT, Timothy W
• Format: Journal Article
• Language: English
• Published: Philadelphia, PA American Association for Cancer Research 01.08.2002
• Subjects: Animals; Antineoplastic Agents, Alkylating - toxicity; Bile Duct Diseases - chemically induced; Bile Duct Diseases - metabolism; Bile Duct Diseases - pathology; Bilirubin - blood; Biological and medical sciences; Cell Division - drug effects; Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme System - metabolism; Dioxoles - toxicity; Drug toxicity and drugs side effects treatment; Female; Gene Expression - drug effects; Isoquinolines - toxicity; Liver - drug effects; Liver - metabolism; Liver - pathology; Liver - physiology; Liver Diseases - blood; Liver Diseases - pathology; Medical sciences; Pharmacology. Drug treatments; Rats; Rats, Wistar; Tetrahydroisoquinolines; Toxicity: digestive system; Marine animal; Antineoplastic agent; Intravenous administration; Rat; Toxicity; Liver; Hepatic disease; Biliary tract disease; Urochordata; Alkaloid; Hepatobiliary; Gene; Female; Isoquinoline derivatives; Rodentia; Animal origin; Prochordata; Hepatobiliary disease; Gene expression; Vertebrata; Chemotherapy; Mammalia; Animal; Digestive diseases; Invertebrata

Ecteinascidin-743 (ET-743) is a novel marine-derived anticancer drug with clinical activity in soft tissue sarcoma and ovarian cancer. Reversible transaminitis and subclinical cholangitis have frequently been described in patients who receive ET-743. To facilitate understanding of this adverse effec...